CA
TRVI icon

CoreCap Advisors’s Trevi Therapeutics TRVI Stock Holding History

CoreCap Advisors’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$336 Buy
+18
New +$262 ﹤0.01% 2930

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

CoreCap Advisors's TRVI Position: Q2 2026 in Review

CoreCap Advisors opened a new position in Trevi Therapeutics (TRVI) in Q2 2026: 18 shares worth $336. The stake represents ﹤0.01% of the portfolio and ranks #2930 among its holdings.

219 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • CoreCap Advisors held 18 shares of Trevi Therapeutics worth $336 as of Q2 2026.
  • Trevi Therapeutics was a new CoreCap Advisors position in Q2 2026.
  • Trevi Therapeutics made up ﹤0.01% of CoreCap Advisors's portfolio in Q2 2026, its #2930 holding.
  • 219 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on CoreCap Advisors's 13F filing for Q2 2026, filed 6 Jul 2026.